Ocumetics Technology Corp. (TSXV: OTC) (OTCQB: OTCFF) (FRA: 2QBO) has announced a series of operational and corporate updates, including positive six-month clinical results from its first-in-human (FIH) study and the completion of a next-generation accommodating intraocular lens. The company, which develops advanced vision restoration technologies, is now advancing to Group Two clinical surgeries, with manufacturing underway and regulatory milestones achieved.
The six-month follow-up data from Group One patients demonstrated encouraging safety and performance outcomes, with successful implantation procedures and favorable post-operative results. Notably, one patient previously considered legally blind is now qualified to drive. These outcomes have supported the decision to proceed to Group Two surgeries, which remain on track for Q3 2026 in Mexico City under Principal Investigator Dr. Raphael Vasquez.
Ocumetics has completed development of its next-generation solid-state accommodating intraocular lens, which incorporates a one-piece design that eliminates internal interface materials such as air, water or oil. The redesigned lens is expected to improve manufacturability, surgical handling, long-term reliability and accommodative performance. Manufacturing has commenced with German partner Amiplant GmbH in preparation for Group Two surgeries.
To fund the next phase of clinical development and accelerate commercialization, the company has launched a financing initiative. Proceeds will support completion of Group Two surgeries, finalize manufacturing and quality verification, advance regulatory programs, and continue strategic partnership discussions. The company has already met with representatives from four of the world's seven largest ophthalmic companies, with follow-up discussions tentatively scheduled for early Q4 2026 following the availability of one-month patient results from Group Two.
All regulatory requirements necessary to proceed to Group Two patient enrollment have been successfully completed. Following manufacturing and product release activities, patient recruitment and surgical scheduling will commence. Management believes that positive one-month results from Group Two patients will represent a significant value-creation milestone as the company advances toward larger clinical studies, regulatory submissions and eventual commercialization.
The next-generation lens offers several expected benefits, including enhanced accommodative performance, simplified architecture, improved manufacturing consistency, and optimized surgical implantation characteristics. The company intends to use this redesigned lens for the upcoming Group Two surgeries, delivered with an updated lens delivery system incorporating improvements from preclinical work and Group One feedback.
Ocumetics continues to engage with leading global ophthalmic organizations for potential strategic partnerships and commercialization opportunities. Based on feedback received, several organizations have expressed interest in reviewing additional clinical data after Group Two surgeries. Management believes discussions validate the commercial potential of the Ocumetics Lens to address a significant unmet need in vision restoration following cataract surgery.
With positive six-month clinical data, the next-generation lens design completed, manufacturing underway, regulatory milestones achieved, and strategic discussions continuing, Ocumetics believes it is well positioned to execute the next phase of its clinical development strategy. The company remains focused on successfully completing Group Two FIH surgeries, advancing regulatory initiatives, and building strategic relationships to support long-term commercialization.
For further information, refer to the original press release at https://www.newmediawire.com.
